Link above if positive article on ELTP
In July 2024 Zacks Research initiated coverage of ELTP. They then posted a positive article on August 16th 2024. ELTP went on a run of 2600% over the next 12 months.
Since that time, Elite Pharmaceuticals has increased revenues by 300%, positive BE on an anticonvulsant, got a new FDA approval on a manufacturing site to 5x production runway, and filed an Abbreviated Novel Drug Application (they have an impeccable record on approval rates) on a drug with a $26 Billion IQVIA market size, hired Jeffries as their M&A consultant to seek opportunities to sell the company and have paid off basically all of their debt.
There is one single thing missing from this company - volume. This company isn’t an “if” - it’s a “when”.
CEO stated this month that the company has outgrown the OTC and if they don’t find a buyer at the right price, they will uplist. Within a year they should be on track to grow revenue another 300 to 350% (8% market penetration on new drugs even after accounting for 80% market shrinkage).
One final point. At that point…they will be peeling off enough cash to buyback 50% of outstanding shares over a 6 month period.
Once enough investors get a whiff of the value…the volume problem disappears and this goes parabolic.
DCF value ranges for this company on SimplyWallSt sit at $3+
